ECT204

DB18605InvestigationalCell transplant therapies

ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

Mechanism
Curator reviewed
Code names
ECT-204

Resolves to

Targets
P51654GPC3

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with ECT204, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In